Time to Reconsider Aldeyra Therapeutics Inc (NASDAQ:ALDX) After Less Short Sellers?

April 17, 2018 - By Richard Conner

Investors sentiment decreased to 1.62 in 2017 Q4. Its down 1.51, from 3.13 in 2017Q3. It is negative, as 5 investors sold Aldeyra Therapeutics, Inc. shares while 8 reduced holdings. 9 funds opened positions while 12 raised stakes. 9.98 million shares or 45.35% less from 18.26 million shares in 2017Q3 were reported.
58,243 were accumulated by Woodstock. Fmr Ltd Co holds 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) or 1.61 million shares. Vanguard Grp accumulated 0% or 698,534 shares. Royal Bancshares Of Canada reported 0% stake. Perceptive Advsr Ltd Liability holds 0.7% or 3.09M shares in its portfolio. The Australia-based Macquarie Grp Inc Ltd has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Alphaone Investment Serv Limited Liability Company has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Ardsley Advisory Prtnrs has invested 0.04% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Northern Tru Corp accumulated 35,861 shares. Mangrove Partners invested in 164,384 shares or 0.15% of the stock. Peddock Capital Advisors Lc invested 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Adage Ptnrs Grp Incorporated Limited Liability Co holds 693,000 shares. Prelude Cap Mgmt Limited Liability Company stated it has 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Tower Rech Cap Ltd Liability (Trc) owns 24 shares or 0% of their US portfolio. Sphera Funds Management holds 0.83% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 1.04 million shares.

The stock of Aldeyra Therapeutics Inc (NASDAQ:ALDX) registered a decrease of 0.33% in short interest. ALDX’s total short interest was 306,000 shares in April as published by FINRA. Its down 0.33% from 307,000 shares, reported previously. With 94,400 shares average volume, it will take short sellers 3 days to cover their ALDX’s short positions. The short interest to Aldeyra Therapeutics Inc’s float is 8.45%.

The stock increased 1.43% or $0.1 during the last trading session, reaching $7.1. About 16,852 shares traded. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 55.45% since April 17, 2017 and is uptrending. It has outperformed by 43.90% the S&P500.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $139.62 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjgren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 2 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics had 4 analyst reports since October 24, 2017 according to SRatingsIntel. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, November 9. Cantor Fitzgerald initiated Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) rating on Tuesday, October 24. Cantor Fitzgerald has “Buy” rating and $22.0 target. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, March 29.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: